Skip to main navigation Skip to search Skip to main content

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells

  • Warren Fiskus
  • , Christopher P. Mill
  • , Behnam Nabet
  • , Dimuthu Perera
  • , Christine Birdwell
  • , Taghi Manshouri
  • , Bernardo Lara
  • , Tapan M. Kadia
  • , Courtney DiNardo
  • , Koichi Takahashi
  • , Naval Daver
  • , Prithviraj Bose
  • , Lucia Masarova
  • , Naveen Pemmaraju
  • , Steven Kornblau
  • , Gautam Borthakur
  • , Guillermo Montalban-Bravo
  • , Guillermo Garcia Manero
  • , Sunil Sharma
  • , Matthew Stubbs
  • Xiaoping Su, Michael R. Green, Cristian Coarfa, Srdan Verstovsek, Joseph D. Khoury, Christopher R. Vakoc, Kapil N. Bhalla

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small molecule targeted-inhibition of GFI1/LSD1 on active enhancers, altering gene-expressions and inducing differentiation and lethality in AML and (MPN) sAML cells. A protein domain-focused CRISPR screen in LSD1 (KDM1A) inhibitor (i) treated AML cells, identified BRD4, MOZ, HDAC3 and DOT1L among the codependencies. Our findings demonstrate that co-targeting LSD1 and one of these co-dependencies exerted synergistic in vitro lethality in AML and post-MPN sAML cells. Co-treatment with LSD1i and the JAKi ruxolitinib was also synergistically lethal against post-MPN sAML cells. LSD1i pre-treatment induced GFI1, PU.1 and CEBPα but depleted c-Myc, overcoming nongenetic resistance to ruxolitinib, or to BETi in post-MPN sAML cells. Co-treatment with LSD1i and BETi or ruxolitinib exerted superior in vivo efficacy against post-MPN sAML cells. These findings highlight LSD1i-based combinations that merit testing for clinical efficacy, especially to overcome nongenetic therapy-resistance in AML and post-MPN sAML.

Original languageEnglish
Article number98
JournalBlood Cancer Journal
Volume11
Issue number5
DOIs
StatePublished - May 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells'. Together they form a unique fingerprint.

Cite this